C&L: Alethia BioTherapeutics names Cornellier new CEO

Alethia BioTherapeutics has appointed Yves Cornellier as president and CEO. He had been senior vice president, business development for LAB International since October 2003, subsequent to the acquisition of Seyvika Pharmaceuticals, of which he was the founder.

David R. Brennan will take over as CEO of AstraZeneca on January 1 when Sir Tom McKillop resigns. Brennan is an executive director of AstraZeneca and executive vice president, North America, responsible for the company's business in the US and Canada.

Eric J. Leire, MD, MBA, was named CEO of ParinGenix. He previously served as president and CEO of APT Therapeutics.

Adolor CEO Bruce Peacock is leaving the company to run a chain of low-cost health clinics. David Madden, the current chairman of the company's board of directors, was elected the interim president and CEO to replace Peacock.

Gary Schweikhardt, co-founder and CEO of Epigenomics' US subsidiary, in Seattle, will retire at the end of 2005 due to personal reasons.

MTM Laboratories has named Robert Silverman president of its new US subsidiary. For the past 18 months, Silverman has provided strategic management consulting services to MTM through his company, RS Consulting.

Jack Armstrong, Jr., executive vice president and COO of Genaera, has been promoted to president and COO.

Michael Cross, Viventia Biotech's COO, has resigned from his position for personal reasons.

Mark H. Burroughs, Osteotech's vice president, finance and treasurer, has been named to succeed Michael J. Jeffries as executive vice president, CFO and secretary.

Structural GenomiX has named James Rotherham as CFO and Peter Myers, PhD, as vice president of drug discovery.

Loretta M. Ucelli, executive vice president for communications and external affairs at Columbia University, and former White House communications director, has been named senior vice president, corporate communications of Pfizer.

Gilead Sciences has promoted Gregg Alton to senior vice president and general counsel and Taiyin Yang, PhD, to senior vice president, pharmaceutical development and manufacturing.

Dr. Michael N. Helmus has been named to the position of senior vice president, BioPharma for Advance Nanotech. Before joining Advance Nanotech Dr. Helmus served as the vice president, advanced biomaterials at Boston Scientific.

ImClone Systems has named Dvorit Samid, PhD, vice president, medical affairs.

Xoma has appointed Alan M. Solinger, MD, as vice president of clinical immunology. Dr. Solinger was director of clinical research at Amgen.

Acorda Therapeutics has made two new senior management appointments. Gerard A. Cignarella has joined the company as vice president of business development and Herbert Henney III, PharmD, has joined the company as vice president of medical affairs.

Schering-Plough promoted Jacqueline Crew, PhD, to vice president, pharmaceutical sciences quality, Schering-Plough Research Institute. Schering-Plough has also promoted Paul Medeiros vice president, global licensing.

Northwest Biotherapeutics has named Paul Zeltzer, MD, as medical director for the company. Dr. Zeltzer previously directed National Cancer Institute-sponsored clinical trials for leukemia and brain tumors and has edited two major text books in oncology and neuro-oncology.

Stephen G. Sudovar, former president and CEO of EluSys Therapeutics and former president of Roche Laboratories, has been elected to the board of Aastrom Biosciences.

Inhibitex has named Robert A. Hamm to its board of directors.

ChemGenex Pharmaceuticals has named Patrick Burns and Peter Bradfield to its board of directors.

R. Scott Greer has joined CombiMatrix as an advisor. Greer is managing director of Numenor Ventures.

RheoGene has added three new members to its Scientific Advisory Board: Fred H. Gage, PhD, Richard Gregory, PhD, and Inder Verma, PhD.

Suggested Articles

The FDA rejected the new drug application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer at Roche.

Vanda Pharmaceuticals received a Complete Response Letter from the FDA taking issue with a small study testing Hetlioz in jet lag disorder.